Skip to main content
Premium Trial:

Request an Annual Quote

Everlywell Inks Distribution Deal for Cellex Point-of-Care Coronavirus Antigen Test

NEW YORK — Everlywell said on Monday that it has signed an agreement to distribute Cellex's point-of-care SARS-CoV-2 antigen test to organizations and public health agencies in the US.

According to Everlywell, the Cellex qSARS-COV-2 Antigen Rapid Test is designed to be administered by healthcare professionals and includes a disposable rapid antigen testing lateral flow device to detect active SARS-CoV-2 infection.

Under the agreement, Everlywell will begin distribution of the test once it receives Emergency Use Authorization from the US Food and Drug Administration. The Austin, Texas-based company said purchasers of the test will also have access to its Everlywell Lens software, which provides information on the status of tests including registration and results.

Additional terms were not disclosed.

In September, Research Triangle Park, North Carolina-based Cellex — which became the first company to receive FDA EUA for a SARS-CoV-2 serology test in April — partnered with medical software firm Gauss to launch a SARS-CoV-2 antigen test for at-home and point-of-care use.

In May, Everlywell received FDA EUA for its COVID-19 Test Home Collection Kit, which may be used with a number of other SARS-CoV-2 tests including ones from Compass Laboratory Services, Thermo Fisher Scientific, and Gravity Diagnostics